(TSX: CRDL) has seen success under a phase II trial conducted on CardiolRx, which is the company’s lead small molecule drug ...

The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for ...

Cardiol Therapeutics Inc. shares N.CRDL are trading off 7 cents at $1.76.

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Preparations Underway for Phase 3 Ovarian Cancer Trial; Set to Initiate in 1Q25 Imunon, Inc. (NASDAQ:IMNN) previously reported positive topline ...

Most patients with rheumatoid arthritis or spondyloarthritis had significant antibody responses to COVID vaccine boosters, whether or not their immunomodulatory medications were held.

IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

The use of IL-17 inhibitors in patients with psoriasis was associated with an increased risk for fungal infections when compared with other biologics.

Among patients with rheumatoid arthritis, JAK inhibitors were slightly more effective for reducing pain at 3 and 12 months when compared with TNF inhibitors.

Medicenna Therapeutics (MDNA) presented updated clinical results from the ongoing monotherapy dose expansion and combination dose escalation portions of the Phase 1/2 ABILITY-1 study evaluating MDNA11 ...

Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...